HCW Biologics News

Latest HCW Biologics Stock News & HCWB Headlines

HCW Biologics' Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer
HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company's Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer's 41st Annual Meeting
HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing
HCW Biologics Inc. (NASDAQ:HCWB) Shares Shorted: Short Interest Up 557.1% in September
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
HCW Biologics Announces Pricing of $1.5 Million Private Placement
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
HCW Biologics' TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

oinCodex Android App
CoinCodex Mobile App
Market Closed

HCWB
HCW Biologics
$ 0.7731
-3.43%   Last 24H
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Updated 2 days ago